Key figures: Harald zur Hausen (German Cancer Research Center, Heidelberg); Françoise Barré-Sinoussi (Institut Pasteur, Paris); Luc Montagnier (Institut Pasteur, Paris); Karolinska Institute Nobel Committee (Stockholm, Sweden)
Summary
On October 6, 2008, the Nobel Assembly at Karolinska Institutet announced the 2008 Nobel Prize in Physiology or Medicine, divided between two landmark discoveries in virology. One half was awarded to Harald zur Hausen (German Cancer Research Center, Heidelberg) for his discovery that certain strains of human papillomavirus (HPV) cause cervical cancer. The other half was jointly awarded to Françoise Barré-Sinoussi and Luc Montagnier (both Institut Pasteur, Paris) for their 1983 discovery of human immunodeficiency virus (HIV), the pathogenic retrovirus responsible for AIDS.
The prize award — 10 million Swedish kronor (approximately $1.4 million USD in 2008) — was split: zur Hausen received half, Barré-Sinoussi and Montagnier shared the other half equally.
The Discovery of HIV
Background
By 1981, physicians in the United States were observing a novel pattern of rare opportunistic infections — Pneumocystis carinii pneumonia, Kaposi’s sarcoma, and severe immunodeficiency — in previously healthy young men. The U.S. Centers for Disease Control and Prevention formally reported the syndrome in June 1981, initially describing it as affecting gay men. By 1982 the condition was named Acquired Immunodeficiency Syndrome (AIDS). Within two years, it became clear that the syndrome could be transmitted through blood transfusions and intravenous drug use, indicating an infectious agent.
Barré-Sinoussi and Montagnier’s Work
In early 1983, Françoise Barré-Sinoussi and Luc Montagnier at the Institut Pasteur’s Laboratory of Viral Oncology in Paris studied lymph node tissue samples obtained from a patient presenting with swollen lymph nodes (lymphadenopathy) — a condition associated with early-stage AIDS. They isolated the lymphocytes, cultured them, and detected the presence of reverse transcriptase — an enzyme specific to retroviruses, which replicate by first transcribing their RNA genome into DNA. This reverse transcriptase signature confirmed they were dealing with a retrovirus.
Electron microscopy revealed viral particles budding from infected T-lymphocytes with characteristics distinct from previously known retroviruses, including HTLV (human T-cell lymphotropic virus) which had been studied by Robert Gallo’s team at the U.S. National Institutes of Health.
Their results were published in the journal Science on May 20, 1983, in a paper titled “Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS).” They named the virus Lymphadenopathy-Associated Virus (LAV). In 1986, international consensus renamed it HIV-1.
The discovery enabled:
- Development of blood-screening tests that prevented HIV transmission through transfusions (introduced 1985)
- Identification of drug targets leading to the first antiretroviral, zidovudine (AZT), approved by the FDA in 1987
- Subsequent development of combination antiretroviral therapy (ART), introduced 1996, which transformed AIDS from a near-universally fatal disease into a manageable chronic condition
The Gallo Controversy
The Nobel committee’s decision to award Barré-Sinoussi and Montagnier — and not Robert Gallo — was noted by the scientific community. Gallo’s laboratory at the U.S. National Institutes of Health had, in 1984, published papers establishing that the retrovirus (which Gallo called HTLV-III) causes AIDS and developed the first blood-antibody test. A dispute over priority followed, since the Pasteur team had sent samples of their virus (LAV) to Gallo’s lab in 1983. Congressional hearings led by Representative John Dingell and an inquiry by the NIH/HHS Office of Scientific Integrity (final report 1991) found that a virus in Gallo’s lab had originated from the Pasteur sample through cross-contamination; Gallo acknowledged the accidental use but was ultimately cleared of deliberate misconduct. A 1987 agreement between the U.S. and French governments had already split patent royalties and credited both teams, and the Nobel Committee’s 2008 decision implicitly affirmed the priority of the Pasteur discovery.
Harald zur Hausen and HPV
Background
Cervical cancer killed an estimated 275,000 women worldwide per year by the early 2000s, making it the second most common cancer in women. The disease’s cause had been debated for decades. Some researchers hypothesized herpes simplex virus (HSV) as the causative agent; others suspected a sexually transmitted infection given the epidemiological pattern.
Zur Hausen’s Research
Starting in the late 1970s at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg, Harald zur Hausen systematically investigated whether papillomaviruses — a large family of DNA viruses causing warts in animals and humans — might cause cervical cancer. His laboratory conducted molecular hybridization experiments: probing cervical cancer tissue samples with radioactively labeled HPV DNA to detect viral sequences integrated into tumor cell genomes.
In 1983 and 1984, zur Hausen and his team published landmark papers demonstrating the presence of two specific HPV strains — HPV-16 and HPV-18 — in the majority of cervical cancer biopsies. Subsequent research confirmed that HPV-16 and HPV-18 together account for approximately 70% of all cervical cancers worldwide. His team showed that the viral E6 and E7 oncoproteins from these strains inactivate tumor suppressor proteins p53 and pRb respectively, deregulating cell growth and enabling malignant transformation.
This research directly led to:
- Gardasil (Merck): quadrivalent HPV vaccine targeting HPV-6, 11, 16, and 18; FDA-approved in June 2006; the first vaccine specifically designed to prevent cancer
- Cervarix (GlaxoSmithKline): bivalent vaccine targeting HPV-16 and 18; FDA-approved in 2009
- Gardasil 9 (Merck): nine-valent vaccine approved 2014; covers approximately 90% of cervical cancer-causing strains
The WHO estimated in 2008 that widespread HPV vaccination programs could prevent more than 200,000 cervical cancer deaths per year globally.
Significance
The 2008 Nobel Prize in Medicine recognized two discoveries with exceptional humanitarian impact, both emerging from fundamental virology research and both reshaping major public health challenges:
HIV/AIDS Impact
By 2008, an estimated 33 million people were living with HIV worldwide, according to UNAIDS. Approximately 2 million people died of AIDS-related illness in 2007 alone. Since the epidemic began in the early 1980s, AIDS had claimed more than 25 million lives. The discovery of HIV by Barré-Sinoussi and Montagnier enabled the entire cascade of HIV/AIDS science: diagnostics, epidemiology, antiretroviral drug development, and vaccine research. Without the isolation of HIV in 1983, the pandemic would have been far more catastrophic — blood transfusion transmission alone had already infected tens of thousands by the time screening was introduced in 1985.
HPV/Cancer Prevention
Zur Hausen’s discovery represented the validation of a central hypothesis in viral oncology: that oncogenic viruses directly drive human cancers through integration of viral DNA and disruption of tumor suppressor pathways. The HPV vaccines developed from his work represent one of the most significant cancer prevention advances in history. Clinical trials demonstrated vaccine efficacy above 95% in preventing infection by the targeted HPV strains in vaccine-naive populations.
Broader Implications
Together, the awards underscored that decades of basic virology research — often pursued without immediate medical application in mind — can yield transformative public health tools. Both discoveries occurred in the 1970s–1980s under significant pressure (the AIDS crisis) and skepticism (the cancer-virus hypothesis), and the Nobel Prize in 2008 represented retrospective recognition of their lasting global importance.
Sources
- The 2008 Nobel Prize in Physiology or Medicine, NobelPrize.org
- Karolinska Institute Prize Announcement and Press Release
- Wikipedia: 2008 Nobel Prize in Physiology or Medicine
- Barré-Sinoussi & Montagnier (1983): “Isolation of a T-Lymphotropic Retrovirus,” Science, 220(4599):868–871
- UNAIDS: 2008 Global AIDS Epidemic Update
- Wikipedia: Harald zur Hausen